RxDoctor Payments Data

Jeffrey Dendy, MD

Cardiovascular Disease · Nashville, TNNPI 1164579058

Payments from drug & device makers

$352in general payments, 2019–2025

Across 19 payments — averaging $18.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$117
  • Heartflow, Inc.$112
  • Pfizer$36
  • Amgen$30
  • Boehringer Ingelheim$18
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$14
  • plus $25 from 2 others

What the payments were for

  • Food & beverage$352100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$352 in reported general payments places this provider in the 25th percentile of 429 cardiovascular disease providers in Tennessee.

See all cardiovascular disease providers in Tennessee

Medicare billing

Part B allowed, 2024
$74,448
Medicare patients
1,529
Services billed
2,265

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban97$137,508
JardianceEmpagliflozin38$61,272
EntrestoSacubitril/Valsartan21$35,435
Repatha SureclickEvolocumab19$21,327
Repatha PushtronexEvolocumab18$14,859
FarxigaDapagliflozin Propanediol15$11,856
Praluent PenAlirocumab14$10,928
BrilintaTicagrelor11$6,690
Prasugrel Hcl14$2,393
Atorvastatin Calcium134$1,572
Metoprolol Succinate59$1,105
Rosuvastatin Calcium79$1,090
Potassium Chloride35$1,010
Bumetanide13$977
Losartan Potassium74$742

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$36$137,50897 claims
Boehringer IngelheimJardiance$18$61,27238 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 429 cardiovascular disease providers in Tennessee.

Other cardiovascular disease in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →